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Abstract 
Dendritic cell-derived exosomes (Dex) are nanoparticules (50-100 nm in diameter) originating from late endosomes. 
These vesicles are secreted by living dendritic cells (DCs) in the extracellular milieu and have demonstrated the capacity 
to activate innate and adaptive immunity. These immuno-stimulatory properties have stimulated researchers to use Dex 
as a cell free vaccine. The development of a production process following good laboratory practices haallowed the use 
of Dex in vaccination protocols in patients in the early 2000s. However, no modulation of adaptive immune responses 
was observed in these clinical trials. Thus the scientific community attempted to decipher mechanisms of action 
involved in the establishment of an effective immune response after Dex vaccination. The results stressed that the 
immunogenicity of Dex reflects the state of maturation of DCs. Taking into account these new knowledge, our team 
developed a new generation of Dex capable of inducing immune cellular responses against tumor antigens. Their 
effectiveness is currently being evaluated in patients suffering from non small cell lung cancer. 
Running title:  Dendritic cell-derived exosomes as cell free vaccine 
Key words: Dendritic cell, exosomes, cancer, immunotherapy 
Abbreviations: Dendritic cells (DC), DC-derived exosomes (Dex), Natural killer (NK), Toll like receptor (TLR), 
Antigen presenting cell (APC), Monocyte derived-denritic cells (MD-DC). 
 
I) Dendritic cell-derived exosomes: from 
basic science to clinical trial 
The interest for Dex began in 1998 when it was shown 
that these vesicles secreted into the culture supernatant 
of immature dendritic cells (immature Dex or "iDex") 
could induce stabilization and regression of tumors in 
mice. These antitumor effects induced by iDex pulsed 
with tumor antigens were dependant on CD8+ T cells in 
mice (Zitvogel et al., 1998). Subsequently, it was 
demonstrated that iDex could activate CD4+ T cells by 
transferring MHC-II/antigen complexes to a recipient 
DC (Théry et al., 2002) and that human iDex could also 
transfer MHC-I/antigen complexes to a recipient DC 
for the polarization of Tc1 CD8+ T cells (André et al., 
2004). Thus, iDex do not activate T lymphocytes 
directly but need to be transferred on DCs. Studying 
different population of DCs that could be able to 
present Dex for the initiation of CD4+ T cell responses, 
CD8α- DCs were demonstrated to have the ability to 
present iDex's MHC-II/antigen complexes in vitro 
(Théry et al., 2002). However, in vivo data suggested 
that endogenous CD8α+ DCs were the main recipients 
of exosomes without the need for internalization and 
processing, LFA-1 being required for Dex capture 
(Segura et al., 2007). Moreover, the necessity to 
administer an endogenous DCs' maturation agent (ie 
TLR-3 or -9) along with iDex, in vivo in mice, 
confirmed that Dex's MHC/antigen complexes required 
the intervention of an antigen-presenting cell to initiate 
a Tc1 immune response (Chaput et al., 2004). 
Therefore, iDex promote the exchange of functional 
MHC/antigen complexes between DCs. Such a 
mechanism could increase the number of antigen 
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presenting DCs thus amplifying the initiation of 
adaptive immune responses. These results provide a 
rational for the use of iDex as a therapeutic vaccine in 
patients bearing advanced cancer. 
After the development of a production method 
following good laboratory practices (Hsu et al., 2003; 
Lamparski et al., 2002), two phase I clinical trials using 
autologous iDex pulsed with MAGE-3 peptides in 
patients with stage III/IV melanoma (French trial) nd 
lung cancer (US trial) allowed us to monitor 
immunological responses. At this time iDex were 
injected without any adjuvant. These trials aimed at 
evaluating the feasibility of Dex production by 
autologous monocyte-derived DCs and the safety of 
Dex inoculation. Secondary endpoints were the 
immunomonitoring of peptide specific CD4+ and CD8+ 
T cell responses restricted by exosomal MHC class II 
and I molecules. Fifteen patients were included in the 
french trial and thirteen in the US trial. Feasibility and 
tolerance were good; however, no T cell responses 
were pointed out after iDex vaccinations (Escudier et 
al., 2005; Morse et al., 2005). The discrepancy betwe n 
some clinical responses and the lack of any detectable 
T cell responses (Tetramer stainings, Elispots) 
prompted the search for alternate effector mechanisms 
accounting for the tumoricidal activity. We studied NK 
activity in patients enrolled in these clinical trials and 
we could show that iDex were able to restore NK cell 
activity in half of treated patients (Chaput et al., 2006; 
Viaud et al., 2009). All of these preclinical and clini al 
studies have led to improve this vaccine approach in 
order to obtain Dex that could activate an effective 
adaptive immune response in vivo. 
II) Strategies to improve Dex 
immunogenicity 
Three strategies were explored to improve the 
antitumor efficacy of Dex: as already mentioned above 
the concomitant injection of an immunological 
adjuvant (TLR-3 or -9) (Chaput et al., 2004; Guo et al., 
2008), inhibition of CD4+CD25+Foxp3+ regulatory T 
cells (Treg) (Taïeb et al., 2006) and finally the use of 
mature DC to produce Dex (mDEX) (Bianco et al., 
2007; Qazi et  
al., 2009; Segura et al., 2005a, Segura et al., 2005b; 
Sprent, 2005). The role of Treg in restricting T cell 
based-immune responses has gained renewed 
recognition. Cyclophosphamide (CTX) at immuno- 
potentiating doses has been shown to inhibit 
CD4+CD25+ Treg cell activity (Ghiringhelli et al., 
2004; Ghiringhelli et al., 2007). Therefore, we 
investigated the combined effects of CTX and iDex to 
elicit antitumor immunity leading to tumor rejection in 
the poorly immunogenic B16F10 melanoma model in 
mice (Taïeb et al., 2006). iDex-mediated anti-tumor 
effects were dramatically improved in CTX treated 
animals. CTX administrated 6 days before iDex 
vaccination was able to boost peptide specific 
secondary responses as assessed by immunomonitoring 
using specific fluorescent tetramers and IFNγ secretion 
by T cells after in vitro stimulation. Adoptive transfer 
of Treg curtailed CTX/iDex synergistic anti-tumor 
effects confirming the inhibiting role of Treg (Taïeb et 
al., 2006). Modulation of Dex bioactivity through 
modulation of DCs maturation stage was first described 
by Robbins' team in 2005 (Kim et al., 2005). This fir t 
study shows that Dex derived from DC treated with IL-
10 are tolerogenic, resulting in the suppression of 
inflammation and collagen-induced arthritis in mice 
(Kim et al., 2005; Ruffner et al., 2009). Thereafter, his 
team and others have shown that the treatment of DCs 
with indoleamine 2,3-dioxygenase (IDO) (Bianco et al., 
2009) or IL-4 (Kim et al., 2007a) but also the loading 
of alloantigens on DCs (Montecalvo et al., 2008; Pêche 
et al., 2003; Pêche et al., 2006) could lead to the 
production of tolerating Dex. Some molecules have 
been identified as responsible for this tolerance: MHC-
II complexes (Kim et al., 2007b), Fas-L (Kim et al., 
2006), CD80 and CD86 (Ruffner et al., 2009) (the two
latter being weakly expressed on iDex). Conversely, it 
appears that exosomes secreted by mature DCs are 
immunogenic (mDex). Indeed, Dex produced from 
LPS-matured DC showed enrichment with ICAM-1 
and CD86 leading to activation of CD4+ and CD8+ T 
cells (Segura et al., 2005b; Sprent, 2005). These studies 
highlighted the fact that Dex can be tailor-made in vitro 
for the treatment of autoimmune diseases, viral 
infection as well as cancer. In our group, we have 
engineered human mDex, respecting good laboratory 
processes (GLP), harboring a phenotype with increased 
expression of MHC complexes and costimulation 
molecules suggesting potent adaptive immunity 
(unpublished data). These second generation mDex are 
currently tested in a phase II clinical trial in non small 
cell lung cancer (NSCLC) bearing patients (Viaud et 
al., 2010). 
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Figure 1. Molecules that influence Dex immunogenicity. Molecules that influence Dex immunogenicity. It is conceivable to think that 
the balance of expression of these markers could guide the immune response. Expression density of these molecules is modified 
according to the signals received by secreting DCs. Thus Dex enriched with antigen-loaded MHC-I,-II molecules, costimulatory molecules 
(CD40, CD80 and CD86), molecules that stimulate innate immunity (IL-15Rα/IL-15, NKG2D-L, proinflammatory cytokines) and molecules 
allowing the up-take by a DC subpopulation (ICAM-1) rather than by macrophages (MFG-E8) should induce potent adaptive and innate 
immune responses rather than ignorance or tolerance. Conversely DCs receiving anti-inflammatory signals (IL-10, TGFβ, IDO, IL-4 ...) 
can produce Dex poorly enriched with costimulatory molecules and ICAM-1 and expressing certain molecules that could directly inhibit 
adaptive immune responses (i, e. FASL) or stimulate tolerance. The biological role of mRNAs and microRNAs and their influence on Dex-
mediated immune responses remain unknown. Finally, several molecules remain to be identified as well as the regulation of their 
expression on Dex. These latter points provide exciting lines of investigation for the future. 
 
III) Molecules that regulate Dex 
immunogenicity (Fig. 1) 
As mentioned above, modification of Dex molecular 
composition influences Dex's immune properties. Thus 
identification of molecules involved in immune 
responses generated by Dex seems paramount. 
Currently few molecules have been clearly identified. 
Some of them incline to immunogenicity: i) MHC 
molecules necessary to generate an adaptive immune 
response ii) CD54/ICAM-1 and mannose/glucosamine-
rich C-type lectin receptor ligands (Hao et al., 2007; 
Segura et al., 2007) that could favor the uptake by 
endogenous DCs iii) B7.2/CD86 and CD54/ICAM-1 
that could induce CD4+ T cell responses (Segura et al., 
2005b) or CD8+ T cell responses (Sprent, 2005), iv) 
and B7.1/CD80 and B7.2/CD86 that could participate 
in DTH reactions (Ruffner et al., 2009) and v) IL-15Rα 
and NKG2D-L that promote the activation and 
proliferation of NK cells (Viaud et al., 2009). Other 
molecules, in contrast, promote tolerance: i) CD95 
ligand/FASL probably in enhancing lymphocytes 
apoptosis (Kim et al., 2006), ii) MFG-E8/lactadherin 
(milk fat globule EGF factor VIII) highly expressed on 
iDex but weakly expressed on mDex (Segura et al., 
2005a) could play a pivotal role in the immunogenicity 
of Dex. Indeed MFG-E8 (MFG-E8 binds to apoptotic 
cells, activated platelets, and phosphatidylserine-
expressing cells via the C-domains and anchors themo 
macrophage integrins via its RGD sequence in the EGF
domain) is involved in phagocytosis and destruction of 
apoptotic cells by macrophages (Hanayama et al., 
2002) and could play a major role in maintaining 
peripheral tolerance (Asano et al., 2004; Hanayama et 
al., 2004). Thus highly MFG-E8-expressing exosomes 
could target dying cells and/or apoptotic bodies 
ensuring their clearance leading to a silent cell dath 
for the immune system. Recently, some studies have 
suggested that iDex (enriched with MFG-E8) rescue 
septic animals via MFG-E8 thanks to a systemic 
inflammatory response decrease in sepsis by enhancing 
apoptotic cell clearance (Miksa et al., 2009; Miksa et 
al., 2006). By cons, mDEX expressing strongly ICAM-
1 and weakly MFG-E8 could be mainly targeted on 
endogenous DCs and therefore be immunogenic 
(Segura et al., 2005a; Segura et al., 2005b; Segura et 
al., 2007). Besides these molecules that have been w ll 
studied during the development of an immune response 
induced by Dex, other mediators could participate. 
Some researchers have deliberately modified DCs to 
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make them express pro/anti-inflammatory cytokines 
leading to production of Dex with modified immune 
capacities (Dai et al., 2006). Recently, it has been 
shown that Dex could contain bioactive cytokines. One 
work suggested an alternative model of IL-1β release 
that may involve the P2X7R-induced formation of 
multivesicular bodies which contain exosomes with 
entrapped IL-1β and other inflammasome components 
(Qu et al., 2007). Moreover, C. Obregon and colleagu s 
have demonstrated that Dex could represent important 
carriers of TNF-α (Obregon et al., 2009) highlighting 
the key role of DC-derived exovesicles, not only in 
adaptive immunity, but also in innate immunity by 
triggering innate immune responses and activating 
neighboring epithelial cells to release cytokines and 
chemokines, thereby amplifying the magnitude of the 
innate immune response. Finally, immunoregulation of 
Dex could also be controlled by their microRNAs 
content. Indeed, DC maturation signals lead to the 
induction or reduction of microRNAs' pool, some of 
them being pro-inflammatory while others anti-
inflammatory (Lu and Liston, 2009; Rodriguez et al., 
2007). Given that exosomes contain microRNAs that 
can be transferred to a target cell (Valadi et al., 2007) 
and knowing that secreted microRNAs could be mainly 
contained in exosomes (Kosaka et al., 2010) (exosome  
being resistant to complement attack (Clayton et al., 
2003) and protected from RNAses (Valadi et al., 
2007)), it is conceivable that the microRNAs 
composition could influence the pro- or anti-
inflammatory properties of Dex; however this 
hypothesis remains to be confirmed. 
IV) Conclusion and perspectives 
Although the full understanding of the significance of 
Dex requires additional studies, these vesicles proved 
to be a naturally occurring minimal antigen presenting 
unit that could orchestrate immune responses according 
to various signals received by producing DCs (Théry et 
al., 2009).  
Exosomes are secreted in large quantities by DCs in the 
absence of any stimulation (steady state), in this 
context exosomes might play a role mainly in tissue 
homeostasis in promoting apoptotic body clearance ad 
avoiding harmful inflammation that could lead to 
autoimmune diseases development. By cons, in an anti-
inflammatory (IL-10, TGFβ, IDO ...) or a pro-
inflammatory (LPS, Poly IC, IFNγ, ATP...) context, the 
molecular composition of Dex could play a 
fundamental role in shaping immune responses. Indeed, 
in vivo the targeting to one or the other exosomes 
presenting cell (MFG-E8, ICAM-1 ...), the expression 
of molecules that can regulate immunity (costimulatory 
molecules; FASL ...), the presence of inflammation 
mediators in Dex (IL-1β, TNFα, TGFβ1 ...) but also 
mRNAs or microRNAs content should dictate in vivo 
bioactivity of Dex. The role of Rab27a and Rab27b in 
regulating the secretion of exosomes has recently been 
identified (Ostrowski et al., 2010); this should enable 
us to build tools for the understanding of exosomes' 
role in different pathophysiological contexts. Our 
growing knowledge of the effects of Dex on immune 
responses and their potential use as therapeutic agents 
led us to develop second generation mDex in order to 
propose a maintenance immunotherapy in patients with 
advanced cancer (Fig. 2) (Viaud et al., 2010). During 
this phase II clinical trial, we will have a unique 
opportunity to analyze the immunostimulatory capacity 
of mDex in a dynamic study in patients, to investigate 
their protein and nucleic acid content and to correlate 
those parameters with a potential and expected clinica  
efficacy in patients. Together, these studies should 
allow us to identify molecules essential for the 
bioactivity of mDex in vivo in cancer patients. 
 
Figure 2. Phase II clinical trial using mDEX (Dex2 trial). During this bicenter trial (Gustave Roussy and Curie Institutes, France), HLA-
A2+ patients suffering from inoperable NSCLC (Stage IIIB / IV) and responders to induction chemotherapy, will receive Dex-based 
maintenance immunotherapy (oral low dose cyclophosphamide for 3 weeks followed by intradermal vaccinations with mDex pulsed with 
tumor antigens). Clinical response evaluation after 4 and 6 vaccines will allow determining the efficacy of this therapeutic approach. In 
addition, numerous samples (blood and tumor) will allow building a link between mDex immunogenicity and possible clinical responses. 
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